Business Combinations (Narrative) (Detail) shares in Thousands, $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended
	Dec. 21, 2016 USD ($) Contract Subsidiary shares	Mar. 31, 2017 USD ($) shares	Mar. 31, 2017 USD ($) shares	Jun. 30, 2016 USD ($)
Business Acquisition [Line Items]
Cash paid			$ 270,000
Deferred payment		$ 50,000	$ 50,000
Number of shares to be issued | shares		5,122	5,122
Contingent consideration		$ 2,830	$ 2,830
Goodwill		241,741	241,741	$ 67,871
Citron and Lucid
Business Acquisition [Line Items]
Number of national contracts with the Federal Government | Contract	18
Term of national contracts	5 years
Cash paid	$ 270,000
Deferred payment	$ 50,000
Interest rate	5.00%
Number of shares to be issued | shares	5,122
Purchase price, earn-out period	5 years
Purchase price, earn-out amount	$ 50,000
Contingent consideration	2,580	$ 2,697	$ 2,697
Goodwill	173,907
Intangible assets	224,850
Citron and Lucid | Product Rights
Business Acquisition [Line Items]
Intangible assets	$ 135,700
Amortizable period of intangible assets	10 years
Citron and Lucid | Customer Relationships
Business Acquisition [Line Items]
Intangible assets	$ 88,800
Amortizable period of intangible assets	11 years
Citron and Lucid | Trademarks
Business Acquisition [Line Items]
Intangible assets	$ 350
Amortizable period of intangible assets	6 months
Rising Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Number of subsidiary | Subsidiary	2